Trump’s 63 Million Doses of Hydroxychloroquine Could Have Been Great for America

Review of the safety and efficacy of HCQ for the treatment and prevention of COVID-19, with a focus on the political and media landscape surrounding its use. Author reports that the FDA's decision to revoke HCQ's emergency use authorization was based on flawed data and methodology, with the inclusion of overdose cases and inappropriate dosing, and that the FDA further actively discouraged use and portrayed HCQ as unsafe, in contradiction to pre-COVID-19 guidelines and safety data. The author also discusses the biased and inaccurate portrayal of HCQ's safety and efficacy by the media and medical experts, often driven by political opposition. Meta analysis of over 400 studies demonstrates HCQ's effectiveness in early treatment and prophylaxis. Author highlights the significant financial implications of prioritizing expensive, novel treatments over repurposed drugs like HCQ, and concludes that the suppression of HCQ represents a major scandal in American medicine and calls for a full investigation into the matter.